In a summary, our findings first demonstrated that GPM6B not only suppresses glioma stem cell capacity and glioma growth by inhibiting Integrin β1–mediated regulation of β-catenin, but also reduces its own degradation by repressing SOCS3-mediated ubiquitination, thereby stabilizing itself in glioma. Here, GPM6B is linked to central nervous system cancer.